69. The composition of claims 67 or 68, wherein the enteric coating comprises Eudragit® FS30D, PlasAcryl®, Eudragit® S100, Eudragit®L100, Eudragit®L100-55, Eudragit® L30D-55, Eudragit® S, Eudragit®RL30D, Eudragit®RS30D, Eudragit® RS, Eudragit® EC, or mixtures thereof.

70. A composition prepared by the method of claim 63.

71. Use of a therapeutically effective amount of the composition of any of claims 1-60 or 70 in the manufacture of a medicament for treating a gastrointestinal disorder.

72. The use of claim 71, wherein the gastrointestinal disorder is selected from the group consisting of: irritable bowel syndrome (IBS), constipation, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, diverticulitis, visceral pain, abdominal pain, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.

73. The use of claim 72, wherein the gastrointestinal disorder is constipation.

74. The use of claim 73, wherein the constipation is chronic constipation, idiopathic constipation, chronic idiopathic constipation, constipation due to post-operative ileus, or constipation caused by opiate use.

75. The use of claim 72, wherein the gastrointestinal disorder is irritable bowel syndrome (IBS).

76. The use of claim 75, wherein the irritable bowel syndrome is constipation-predominant irritable bowel syndrome (IBS-c), diarrhea-predominant irritable bowel syndrome (IBS-d) or mixed irritable bowel syndromes (IBS-m).

77. The use of claim 72, wherein the gastrointestinal disorder is dyspepsia.

78. The use of claim 72, wherein the gastrointestinal disorder is gastroparesis.

79. The use according to claim 78, wherein said gastroparesis is idiopathic, diabetic or post-surgical gastroparesis.

80. The use of claim 72, wherein the gastrointestinal disorder is chronic intestinal pseudo obstruction.

81. The use of claim 72, wherein the gastrointestinal disorder is Crohn's disease.

82. The use of claim 72, wherein the gastrointestinal disorder is ulcerative colitis.

83. The use of claim 72, wherein the gastrointestinal disorder is inflammatory bowel disease.

84. The use of claim 72, wherein the gastrointestinal disorder is visceral pain.

85. The use of claim 72, wherein the gastrointestinal disorder is diverticulitis.

86. The use of claim 72, wherein the gastrointestinal disorder is abdominal pain.

87. Use of a therapeutically effective amount of the composition of any of claims 1-60 or 70 in the manufacture of a medicament for treating a disorder.

88. The use of claim 87, wherein the disorder is cancer selected from colorectal/local metastasized colorectal cancer, gastric cancer, intestinal polyps, gastrointestinal tract cancer, cancer or pre-cancerous growths or metastatic growths of epithelial cells or polyps of colorectal tissue.

89. Use of a therapeutically effective amount of the composition of any of claims 1-60 or 70 in the manufacture of a medicament for treating or relieving pain.

90. The use of claim 89, wherein the pain is selected from visceral pain; diverticulitis pain; pelvic; abdominal pain; or pain associated with gastrointestinal disorders, venereal diseases, bladder pain syndrome, or interstitial cystitis.

91. Use of the pharmaceutical composition according to any one of claims 1-60 or 70 in the manufacture of a medicament for increasing intestinal motility in a patient.

92. Use of a composition according to any one of claims 1-60 or 70 in the manufacture of a medicament for increasing guanylate cyclase C (GC-C) receptor activity in a biological sample or organism, wherein said biological sample or organism is to be contacted with the medicament.

93. A method of making the composition of any of claims 1-60 or 70, comprising:

i) preparing an aqueous solution comprising linaclotide, or a pharmaceutically acceptable salt thereof; and

ii) applying the aqueous solution to a pharmaceutically acceptable carrier.

94. A composition prepared by the method of claim 93.